Trial results

$SPTX — GlyphAllo

Seaport Therapeutics, Inc. (SPTX) GlyphAllo: trial results in Major depressive disorder (MDD), 2027.

Research by Catalyst Intel

The catalyst

"Topline data from the BUOY-1 trial are expected in the first half of 2027."

— Seaport Therapeutics, 8-K filed 2026-11-02 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

SPTX-GLYPHALLO-2026

Company

Seaport Therapeutics, Inc.

Kind

Trial results

Indication

Major depressive disorder (MDD)

Window

2027-01-01 – 2027-06-30

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.